MedTrace Logo

Relapse Prevention With Varenicline

NCT00944554 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2017-08-03

Study results available
· View outcomes & findings →

Summary

This study aims to determine if varenicline (Chantix®), currently used as a smoking cessation aid, will decrease the likelihood of relapse to smoking following a programmed lapse in the laboratory. The hypothesis is that varenicline will reduce the reinforcing effects of smoking and will delay or prevent relapse compared to placebo.

Conditions

  • Recurrence
  • Smoking Cessation
  • Substance-Related Disorders

Interventions

DRUG

Varenicline

Varenicline given twice a day or five weeks.

DRUG

Placebo

Placebo given twice a day or five weeks.

Sponsors & Collaborators

Principal Investigators

  • Maxine L Stitzer, PhD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00944554 on ClinicalTrials.gov